BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18379033)

  • 1. [Cancer treatment-induced bone loss. Treatment for breast cancer].
    Yamada K; Kohno N
    Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
    Lønning PE
    J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
    [No Abstract]   [Full Text] [Related]  

  • 4. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
    Takahashi S
    Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with bone-targeted agents.
    Wilson C; Coleman RE
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 12. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term implications of bone loss in breast cancer.
    Aapro MS
    Breast; 2004 Dec; 13 Suppl 1():S29-37. PubMed ID: 15585380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiresorptive therapies in oncology and their effects on cancer progression.
    Bundred N
    Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging drugs for the management of cancer treatment induced bone loss.
    Bertoldo F; Pancheri S; Zenari S; Boldini S
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):323-42. PubMed ID: 20377485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.